Oxytrol For Women Draft Questions
This article was originally published in The Tan Sheet
FDA’s draft questions to the NDAC on Merck’s ’s proposed Rx-to-OTC switch of Oxytrol for Women includes one item to vote on – whether consumers can appropriately self-select the product OTC – while also asking for discussion on possible concerns about safety and about the data included in the firm’s NDA.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.